Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
VRVerrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA)

NASDAQ · Currency in USD
$3.53 ▼ -0.30 (-7.83%)
At close: Oct 23, 4:00 PM ET. Market closed.
$3.46 ▼ -0.07 (-1.98%)
Pre-market: Oct 26, 7:52 AM ET

Summary

Previous Close
$3.83
Open
$3.66
Day's Range
$3.40 – $3.75
52 Week Range
$3.28 – $9.82
Volume
21,005
Avg. Volume
60,846
Market Cap
$60.64M
Beta (5Y Monthly)
1.61
PE Ratio (TTM)
--
EPS (TTM)
-$1.46
Earnings Date
Nov 13, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$9.00

Profile: Verrica Pharmaceuticals Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
76
CEO
Jayson Rieger

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications.

Earnings

Next report: Fri, Nov 13, 2026
EPS estimate -$0.45 · Revenue est. $6.20M
DateEst.Actual
Aug 6, 2026-$0.39-$0.62Miss
May 12, 2026-$0.59-$0.41Beat
Mar 11, 2026-$0.43-$0.51Miss
Nov 14, 2025-$1.14-$0.03Beat
Aug 12, 2025-$0.70$0.02Beat
May 13, 2025-$1.23-$1.00Beat

Analyst view

Consensus price target
$9.00 ▲ +155.0%
Range $9.00 – $9.00
Rating: Buy
Buy 60% · Hold 40% · Sell 0%

Get free alerts on VRCA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.